Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 9/20 | 0.59 |
| ▸ | GABRB2 | P47870 | 9/20 | 0.59 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.44 |
| ▸ | GABRP | O00591 | 2/20 | 0.43 |
| ▸ | GABRD | O14764 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.43 |
| ▸ | GABRE | P78334 | 2/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.43 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6870374 | 0.77 | GABRA2 (0.64) | GABRA2GABRB2GABRB3GABRPGABRD | |
| SCHEMBL6867861 | 0.75 | GABRA2 (0.65) | GABRA2GABRB2GABRB3GABRPGABRD | |
| SCHEMBL9214661 | 0.75 | GABRA2 (0.61) | GABRA2GABRB2GABRB3GABRPGABRD | |
| SCHEMBL6870981 | 0.75 | GABRA2 (0.61) | GABRA2GABRB2GABRB3GABRPGABRD | |
| SCHEMBL27257488 | 0.73 | GABRA2 (0.63) | GABRA2GABRB2GABRB3GABRPGABRD | |
| SCHEMBL9219629 | 0.73 | GABRA2 (0.71) | GABRA2GABRB2GABRB3NOTUM | |
| SCHEMBL6055855 | 0.72 | GABRA2 (0.45) | GABRA2GABRB2GABRB3GABRPGABRD | |
| SCHEMBL6866331 | 0.72 | GABRA2 (0.67) | GABRA2GABRB2GABRB3 | |
| SCHEMBL6055869 | 0.71 | GABRA2 (0.47) | GABRA2GABRB2GABRB3GABRPGABRD | |
| SCHEMBL10430968 | 0.71 | GABRA2 (0.57) | GABRA2GABRB2GABRB3GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812241-B2 | FOR PLANTS, HUMANS, VETERINARY MEDICINE | PFIZER INC. | 2004-11-02 | — | — | US | disclosed |
| US-20030130307-A1 | Heterocycles | BANKS BERNARD JOSEPH (GB) | 2003-07-10 | — | — | US | disclosed |
| US-6525079-B2 | Antiparasitic compounds such as 4-(2,2-dibromocyclopropyl)-1-(2,6-dichloro-4-trifluoromethylphenyl)-1,2,3 -triazole | PFIZER INC. | 2003-02-25 | — | — | US | disclosed |
| US-20010005725-A1 | Heterocycles | BANKS BERNARD JOSEPH (GB) | 2001-06-28 | — | — | US | disclosed |
| US-6110958-A | PARASITICIDES | PFIZER INC. (US) | 2000-08-29 | — | — | US | disclosed |
| US-6083965-A | ANTIPARASITIC AGENTS | PFIZER INC (US) | 2000-07-04 | — | — | US | disclosed |
| EP-0957094-A1 | 1-(2-Halogenaryl)azoles as antiparasitic agents | PFIZER INC. (US) | 1999-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130307-A1 | Heterocycles | CYP1A1, CYP2E1, CYP1B1 | GABRA2 2526/4885GABRB2 1986/4885GABRB3 2239/4885 |
| US-20010005725-A1 | Heterocycles | CYP1A1, CYP2E1, CYP1B1 | GABRA2 2526/4885GABRB2 1986/4885GABRB3 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.